AI Article Synopsis

  • Vaginal laxity is a common issue linked to childbirth and is often overlooked in treatment.
  • The Jett Plasma for Her II Study assessed the effectiveness and safety of electroporation therapy in treating this condition, comparing active therapy with a placebo in a controlled study of 91 women.
  • Results demonstrated significant improvements in vaginal laxity and related symptoms, along with an increase in vaginal mucosa thickness, confirming the treatment's effectiveness and tolerability over 12 months.

Article Abstract

Introduction: Vaginal laxity is a widespread and undertreated medical condition associated especially with vaginal parity.

Aim: To evaluate the efficacy and safety of electroporation therapy treatment of vulvovaginal laxity by the Jett Plasma for Her II device.

Methods: The Jett Plasma for Her II Study is a multicentric, prospective, randomized, single-blinded, and controlled study. Women presenting with vaginal laxity were randomized to receive electroporation therapy delivered to the vaginal tissue (active-82 patients) vs. therapy with zero intensity (placebo-9 patients).

Results: A total of 91 subjects whose average age was 48.69 ± 10.89 were included. Due to the results of a one-way analysis of variance, it may be concluded that in the case of the vaginal laxity questionnaire (VLQ), there is a statistically significant difference between actively treated patients and the placebo group (F = 46.91; < 0.001). In the case of the female sexual function index (FSFI), a one-way ANOVA test also showed a statistically significant difference between the actively treated patients and the placebo group (F = 7.97; = 0.005). In the case of the incontinence impact questionnaire-7 (IIQ-7), a one-way ANOVA test showed a statistically significant difference between the actively treated patients and the placebo group (F = 15.51; < 0.001). It confirms that improvement of vaginal laxity is conjoined with benefits in symptoms of urinary incontinence. Biopsy performed after the end of the treatment shows an increase in the vaginal mucosa thickness by an average of 100.04% in the active group. The treatment was well tolerated with no adverse events. No topical anesthetics were required.

Conclusions: Treatments of vulvovaginal laxity by electroporation therapy achieved significant and sustainable 12-month effectiveness. Responses to the questionnaires also suggest subjective improvement in self-reported sexual function, incontinence, sexual satisfaction, and urogenital distress.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573526PMC
http://dx.doi.org/10.3390/jcm12196234DOI Listing

Publication Analysis

Top Keywords

vaginal laxity
16
vulvovaginal laxity
12
jett plasma
12
electroporation therapy
12
statistically difference
12
difference actively
12
actively treated
12
treated patients
12
patients placebo
12
placebo group
12

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!